GBA Presents: RADIO SAVANT-!

vanzandt said:
now would be the worst time to sell Nike. It has $135 in it easy.
More...
Stoney!!!
I told you so!!!
The dow is down 350 points and look at NKE... $122 and in the green. :wtf:

Hey your hypothetical Feb $65 logitech options are down 6%, and like I said, they'll continue to drop, but watch and learn on that.

BYDDF---> Green. :strong:
$26.89
Selling batteries to Sony/Honda.
Selling EV's to the masses in China.

Warren took my advice when I said to buy this last Spring and look what happened:

Warren Buffett's Berkshire Hathaway has slashed its BYD stake by 22% in 4 months - and raked in a roughly $1.2 billion profit on the shares sold :D
 
vanzandt said:
I like AEHR's report.
It's $17.95 after hours as I type.

Buy it.
Stop at $17.50
More...
AEHR----> $19.76 (+14.5%)

If Stoney had done this, we'd have heard about it for a month. :D

stonedinvestor said:
SWING TRADE COMPLETE** ----- NEVER DOUBT THE MASTER BLASTER TED!!!! WHAT DID I TELL YOU....:p

NIKE, Inc. (NKE)<---------------- :fistbump: Along with the options this trade made a whole lot of dough. :cool: I guess that's why I have the top ranked stock thread on ET!!!! and all of NYC-- I checked-- no other stock thread has as many followers!!!!!


GBA TRADE*SELL NKE-> @121.<------------:thumbsup:
More...

For VZ... just another +15% walk in the park.
Feast my children.

Next. :sneaky:
 
stonedinvestor said:
SELL! This hit $20.40 today ////////

This trade made a fortune! $14.75--------$20.00

and that was AFTER a succesfull gummy at lower prices a Twofor!
More...




OUT of This name -- they snuck in an earn report last night----

Aehr Test Systems reports Q2 EPS 16c, consensus 8c 16:21 AEHR Reports Q2 revenue $14.80M consensus $$12.78M.
 
Bunzl seen as 'inflation winner', Barrons reports 19:05 BZLFY Bunzl is seen as an "inflation winner" in an environment where investors looking for more defensive positioning seek out companies that use inflation to their advantage, Briant Swint of Barron's writes. The company has benefited from the pickup in activity emerging from the pandemic, and it has been able to raise prices along the way, the report states.
 
Iridium to partner t with Qualcomm on satellite messaging and emergency services 20:05 IRDM, QCOM Iridium Communications (IRDM) "announced it has entered into an agreement with Qualcomm Technologies (QCOM) to enable satellite messaging and emergency services in smartphones powered by Snapdragon Mobile Platforms. Qualcomm Technologies' new Snapdragon Satellite solution is supported by the fully operational Iridium satellite constellation. Emergency messaging using Snapdragon Satellite is expected to debut starting in the second half of 2023 in premium Android smartphones launched in select regions."

Snowflake initiated with an Overweight at Wells Fargo 04:55 SNOW Wells Fargo analyst Michael Turrin initiated coverage of Snowflake with an Overweight rating and $170 price target.

Equinor upgraded to Buy from Hold at DNB Markets
 
Amarin upgraded to Buy from Hold at Jefferies

Shell says natural gas profit to be 'significantly higher' in Q4 vs. Q3 »

AerCap price target raised to $77 from $66 at Barclays

Borr Drilling upgraded to Buy from Neutral at BTIG 06:11 BORR BTIG analyst Gregory Lewis upgraded Borr Drilling to Buy from Neutral.
 
Sight Sciences upgraded to Buy from Hold at Stifel 06:15 SGHT Stifel analyst Thomas Stephan upgraded Sight Sciences to Buy from Hold with a price target of $15, up from $10.

LifeStance upgraded to Overweight from Equal Weight at Morgan Stanley 06:17 LFST

Boot Barn initiated with a Buy at BofA 06:23 BOOT

Baird upgrades 'differentiated story' Allogene Therapeutics to Outperform 06:40 ALLO Baird analyst Jack Allen upgraded Allogene Therapeutics to Outperform from Neutral with an unchanged price target of $12. The analyst views the stock's current valuation as an attractive opportunity to gain exposure to a "differentiated story" in the allogeneic cell therapy space. Allogene's positive durability results appear differentiated, Allen tells investors in a research note. The analyst sees room for shares to "reserve their downward trend and grind higher in the coming quarters as appreciation for the durability of Allogene's approach grows."

LifeStance upgraded at Morgan Stanley on confidence in new management » 06:52 LFST

Jefferies upgrades 'intriguing small cap value play' Amarin to Buy 06:57 AMRN Jefferies analyst Michael Yee upgraded Amarin to Buy from Hold with a price target of $3, up from $1.30. The shares are trading at a $200M enterprise value, or less than one-times peak European sales, and has some "strategic M&A optionality," a large activist investor working to drive change, and the company is not really burning cash anymore after cutting spending in 2022, Yee tells investors in a research note. In addition, Amarin's U.S. erosion has stabilized three quarters in a row, says the analyst. He also believes Amarin has been getting some good European pricing agreements. Yee calls the company "an intriguing small cap value play."

NewAmsterdam initiated with an Outperform at Credit Suisse 07:03 NAMS
 
You must log in or register to reply here.
Back
Top